What have three decades of gerontology research established about short peptides, and where does the evidence run thin.
A research programme we never covered in medical school
In 1971, a group at the Kirov Military Medical Academy in Leningrad took on a problem unrelated to ageing: radiation protection, keeping immune and haematopoietic function intact in personnel exposed to ionising radiation. Vladimir Khavinson and Vyacheslav Morozov began fractionating animal organ tissue and isolating the low-molecular-weight fractions.
What they found redirected the next fifty years of their work. The thymus fraction restored immune parameters; the pineal fraction shifted neuroendocrine regulation. Each acted mainly on the organ it came from.
That observation produced Thymalin, Epithalamin and Cortexin through the 1980s, moved to the St. Petersburg Institute of Bioregulation and Gerontology in the 1990s, and yielded the short-chain peptides sold today as natural peptide supplements. Khavinson’s group has published north of 800 papers, few reaching English-language curricula.
What peptide bioregulators actually are
A peptide bioregulator is a preparation of short amino acid chains, typically 2 to 7 residues, molecular weight under 5000 Da. Two routes exist: extraction from organ tissue of calves under 12 months, or synthesis from free amino acids matching a sequence in the natural extract. The class is indexed under several names, including peptide bioregulators, bioregulator peptides, Khavinson peptide bioregulators, and geroprotectors.
The defining property claimed is tissue specificity. A liver peptide complex acts on hepatocytes, a cartilage peptide complex on chondrocytes. That is what separates Khavinson bioregulators from ordinary supplementation, and where the peptide therapy benefits in this literature are supposed to originate: not a missing raw material replaced, but a regulatory signal telling existing cells to resume protein synthesis.
Why the body stops making enough of its own?
Endogenous regulatory peptide synthesis declines with age, unevenly across organs. Thymic involution begins in adolescence and is largely complete by the sixth decade, taking naive T-cell output with it; the pineal gland follows a similar curve. Khavinson argued that both sit upstream of nearly everything else in metabolic health, so restoring their signalling should register downstream.
The mechanism claim: peptides that reach the genome
In a 2021 systematic review in Molecules (PMID 34834147), Khavinson and colleagues set out evidence that short peptides penetrate the nucleus, interact with histones and with single- and double-stranded DNA, and recognise sequences in gene promoter regions. The proposed consequence is regulation of DNA methylation, placing them among epigenetic modulators rather than receptor ligands.
The most-cited support is telomere biology. Khavinson, Bondarev and Butyugov reported in 2003 that the tetrapeptide Epitalon induced hTERT expression and telomerase activity in human fetal fibroblasts; a 2004 follow-up found treated cells completed roughly 10 passages past the point where controls stopped dividing.
Cytomax and Cytogen: two branches of one programme
The lines split along the extraction-versus-synthesis divide, and the differences matter more than the marketing
| A | Cytomax(natural) | Cytogen (Synthesised) |
|---|---|---|
| Source | Organ tissue,calves under 12 months | Synthesis from free amino acids. |
| Structure | Mixed complex,upto 5000 Da | Defined di-,tri- or tetra |
| Onset | Slower, cumulative | Faster at the initial stage |
| Line size | 21 preparations | 6 preparations |
| Course | 30 to 45 days | 15 to 30 days |
Cytomax is what most buyers recognize as a natural peptide supplements. The sequencing used in practice runs synthesised first, natural second: a Cytogen to start a response, then the matching Cytomax for the rest of the course.
Inside the clinical files
Between 2005 and 2011, the Institute’s Medical Center documented 27 studies across both lines, all built the same way: open comparative trial, conventional therapy in one arm, conventional therapy plus the bioregulator in the other, markers tracked over 30 to 45 days.
| Preparation | System | Cohort | Arms | Endpoints |
|---|---|---|---|---|
| Bonomarlot | Haematopoietic | 26 women,35-56, IDA | 15/11 | Hb, time to improvement |
| Endoluten | Neuroendocrine | 163 patients,48M/115F | 99/64 | FSH,LH, ESTRADIOL,EVG |
| Chelohart | Cardiovascular | 32 patients,46-72, angina FC I-II | 22/10 | ECG stress response, attack rate |
| Sigumir | Musculoskeletal | 33 patients, 45-78,OA, osteoporosis | 33/31 | Pain, analgesic use |
In the Endoluten neuroendocrine subgroup, serum FSH fell from 89.3 ± 3.5 to 46.8 ± 3.9 IU/ml (reference 1.5–45); controls reached 71.6 ± 6.3, p < 0.05.
The 266-patient study:
The most ambitious human data predates the supplement lines. Khavinson and Morozov followed 266 people over 60 for six to eight years, jointly with the Institute of Gerontology in Kyiv, publishing in Neuroendocrinology Letters in 2003 (PMID 14523363). Participants received Thymalin, Epithalamin or both during the first two to three years.
Reported mortality reduction was 1.6 to 1.8-fold for Epithalamin alone, 2.5-fold for the combination, and 4.1-fold in the subgroup continuing annual courses for six years.
In September 2025, Al-dulaimi and colleagues at Brunel University London published in Biogerontology (DOI 10.1007/s10522-025-10315-x), with no affiliation to Khavinson’s group.
In normal fibroblasts and mammary epithelial cells, they confirmed telomere lengthening under Epitalon via hTERT upregulation. In breast cancer lines, they saw lengthening without a telomerase rise, attributed to alternative lengthening of telomeres. Twenty-two years on, the finding was replicated independently.
Where this leaves us,
A thirty-year programme with hundreds of publications, a coherent mechanism, and several independent replications is not nothing.
For the primary material, Khavinson’s publication list is on PubMed, and the current range of peptide bioregulators is documented by preparation, target system, and composition, showing what these anti-aging formulations contain.
Three things I would like this community’s read on:
- Given the Brunel replication, do Khavinson peptide bioregulators deserve a second look from Western labs, or is the in vitro effect too far from clinical relevance?
- In practice: have patients asked about Khavinson bioregulators, or searched “bioregulators peptides” and turned up already taking them? What did you tell them?
- Where do you set the evidence bar for a supplement class making healthy-ageing claims?
For discussion and education. Not clinical advice.